Skip to main content
GSK to acquire celiac therapy developer Sitari Pharmaceuticals
9/12/2019

GlaxoSmithKline announced it is set to acquire preclinical-stage biotech firm Sitari Pharmaceuticals, although no financial details of the takeover were disclosed. Sitari was founded in 2013 by GSK and Avalon Ventures and its lead candidate is a TG2 inhibitor designed to treat celiac disease, an autoimmune digestive disorder.

Full Story: